echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Rongchang Bio-Injection Vedicutumab will be approved soon

    Rongchang Bio-Injection Vedicutumab will be approved soon

    • Last Update: 2021-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 7th, Rongchang Biologics independently developed a new ADC drug for injection Vidicuzumab (code: RC48, trade name: Aidixi) to enter the approval stage and will be approved in the near future
    .


    This will be the first domestically produced ADC


    ADC drugs are a new type of biological drugs conjugated by monoclonal antibodies, linkers and toxins, which can perform precise attacks on tumor cells
    .


    RC48 adopts a new humanized antibody with stronger affinity and better endocytosis effect, and uses advanced linkers and small molecule toxin drugs, which can effectively kill tumors



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.